OCI is the single platform for your infrastructure, database, application development, and AI needs.

Do more and spend less like Uber 8 by 8 and DataBrix Mosaic.

Take a free test drive of OCI

at Oracle.com slash Wall Street.

From the opinion pages of the Wall Street Journal, this is Potomac Watch.

The Supreme Court hears a case challenging the FDA's rules for Miffapristone,

as Donald Trump gets bond relief from a New York appeals court and a potential

windfall as his social media site truth social goes public.

Welcome I'm Kyle Peterson with the Wall Street Journal.

We are joined today by my colleagues, columnist Alicia Finley, and Kim Strassal.

More than 60% of abortions in the United States last year or about 650,000 were done via medication.

According to the Gutmacher Institute, typically this involves the drug Mifapristone, and the case

Alicia at the Supreme Court today challenges some FDA rules relaxing the

prescribing of Mifapristone, allowing patients to get it via telemedicine and to get it via the mail.

Let's start with a clip of Justice Alana Kagan, asking a question to hear to Solicitor General

Elizabeth Prelegar.

To the government's knowledge, this case marks the first time, and I'm going to say, is it the first time, is it the only time?

Any court has restricted access to an FDA-approved drug by second- second guessing FDA's expert judgment about the

conditions required to assure that drug safe use. Is it still the only time?

That is still to our knowledge the only time a court has done that. We have seen a disturbing

trend of court sometimes also overriding FDA's judgment to try to grant greater access to drugs

when that overrides FDA's expert judgment about what's

...